{"id":556732,"date":"2021-08-09T16:32:01","date_gmt":"2021-08-09T16:32:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=556732"},"modified":"2021-08-09T16:32:01","modified_gmt":"2021-08-09T16:32:01","slug":"the-bronchiectasis-market-outlook-is-expected-to-change-positively-in-the-upcoming-years-because-of-increased-global-healthcare-spending-improved-awareness-and-the-proliferation-of-major-players","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/the-bronchiectasis-market-outlook-is-expected-to-change-positively-in-the-upcoming-years-because-of-increased-global-healthcare-spending-improved-awareness-and-the-proliferation-of-major-players_556732.html","title":{"rendered":"The Bronchiectasis market outlook is expected to change positively in the upcoming years because of increased global healthcare spending, improved awareness, and the proliferation of major players"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1628493025.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"The Bronchiectasis market outlook is expected to change positively in the upcoming years because of increased global healthcare spending, improved awareness, and the proliferation of major players\" src=\"https:\/\/www.abnewswire.com\/uploads\/1628493025.png\" alt=\"The Bronchiectasis market outlook is expected to change positively in the upcoming years because of increased global healthcare spending, improved awareness, and the proliferation of major players\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Bronchiectasis Market <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The launch of therapies such as Brensocatib\/INS 1007 and others are anticipated to provide a major push to the growth of the Bronchiectasis market size in the forecast period 2021-30 in the 7MM.\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/6935435ca49d9e3146a96cf38d496929.jpg\" alt=\"\" \/><\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>DelveInsight&#8217;s <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/bronchiectasis-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Bronchiectasis market report<\/a><\/strong><span> provides a comprehensive understanding of Bronchiectasis, historical and forecasted epidemiology, and Bronchiectasis market trends in the 7MM (the US, EU5 (Germany, Spain, Italy, France, and the UK), and Japan).<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the Important Findings from the Bronchiectasis Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>According to the CHEST Foundation, over <\/span><strong>110,000<\/strong><span> Americans have Bronchiectasis and it affects women more than men.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Insmed Incorporated, Zambon, Novartis, <\/strong><span>and others are among the major companies that are involved in developing novel therapies for Bronchiectasis treatment.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Brensocatib\/INS 1007 (Insmed Incorporated)<\/strong><span> is a novel oral reversible dipeptidyl peptidase 1 inhibitor (DPP1). In June 2020, the US FDA designated it as a breakthrough therapy for the treatment of Non-Cystic Fibrosis Bronchiectasis (NCFB). The drug is currently being evaluated in a Phase III study in Non-Cystic Fibrosis Bronchiectasis patients.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Colistimethate Sodium (Zambon)<\/strong><span> is an antibiotic used to treat <\/span><em>Pseudomonas aeruginosa<\/em><span> infections, and the I-Neb AAD system is an inhalation system that delivers nebulized medications into the lungs. Colistimethate Sodium Powder is being tested in two Phase-III pivotal trials for the prevention of pulmonary exacerbations in adult patients with Non-Cystic Fibrosis Bronchiectasis colonized with <\/span><em>Pseudomonas aeruginosa.<\/em><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>QBW251 (Novartis)<\/strong><span> is a drug that opens the cystic fibrosis transmembrane conductance regulator (CFTR) channel, allowing chloride to be transported. Currently, the drug is in Phase II of development for Bronchiectasis treatment.<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Request for the sample to get a complete overview of the disease @ <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/bronchiectasis-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Types of Bronchiectasis<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The Bronchiectasis market report <\/strong><span>also covers current treatment practices, emerging drugs, Bronchiectasis market share of individual therapies, and current and forecasted Bronchiectasis market Size from 2018 to 2030, segmented by seven major markets.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Bronchiectasis: Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Bronchiectasis is a chronic condition in which the bronchial walls thicken due to inflammation and infection. Exacerbations are periodic flare-ups of breathing difficulties in people with Bronchiectasis. Bronchiectasis symptoms can develop slowly over months or years and worsen over time. Coughing and mucus (sputum) production on a daily basis are the two primary Bronchiectasis symptoms. Bronchiectasis is of two types: Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis (NCFB).<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Bronchiectasis Epidemiology Segmentation<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>The Bronchiectasis report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:<\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Bronchiectasis Total Prevalent Cases<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Bronchiectasis Gender-Specific Cases<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Bronchiectasis Etiology-Specific Cases&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Bronchiectasis Severity-Specific Cases&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Bronchiectasis Age-Specific Cases&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Bronchiectasis Total Diagnosed and Treated Cases&nbsp;<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Bronchiectasis Treatment Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Despite the fact that no medications have been approved by regulatory agencies for Bronchiectasis treatment, a variety of drugs and strategies have shown benefits in improving both quality of life and clinical outcomes. The current Bronchiectasis treatment options include:<\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Antibiotics (Macrolides)<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Bronchodilators&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Anti-inflammatory therapy<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Mucus Thinning Medication<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Bronchiectasis Market<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>The launch of therapies such as <\/span><strong>Brensocatib\/INS 1007, <\/strong><span><strong>Colistimethate Sodium, QBW251<\/strong>,<\/span><span>and others by key pharmaceutical companies such as <\/span><strong>Insmed Incorporated, Zambon, Novartis, <\/strong><span>and several others<\/span><span> is anticipated to provide a major push to the growth of the Bronchiectasis market size in the forecast period 2021-30 in the 7MM.&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Bronchiectasis Pipeline Therapies and Key Companies<\/strong><span>&nbsp;<\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Brensocatib: Insmed Incorporated<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Colistimethate Sodium: Zambon<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>QBW251: Novartis<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>For more details on the emerging drugs and companies, visit <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/bronchiectasis-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">New Treatments for Bronchiectasis<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"64\" \/>\n<col width=\"560\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><span>1.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Key Insights<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>2.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Bronchiectasis: Market Overview at a Glance<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>3.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Executive Summary<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>4.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Organizations<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>5.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Patient Journey<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>6.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Disease Overview: Bronchiectasis&nbsp;<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>7.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Bronchiectasis Epidemiology and Patient Population<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>8.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Bronchiectasis: Country-wise Epidemiology<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>9.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Bronchiectasis Unmet Needs<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>10.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Bronchiectasis Emerging Therapies<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>11.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Bronchiectasis: Market Outlook<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>12.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Bronchiectasis Market Drivers<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>13.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Bronchiectasis Market Barriers<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>14.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Bronchiectasis Market Access and Reimbursement<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>15.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>SWOT Analysis<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>16.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Case studies<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>17.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>KOL Views<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>18.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Appendix<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>19.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Disclaimer<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>20.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>About DelveInsight<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>For rich insights into Healthcare and Pharmaceutical News, visit <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Pharma, Healthcare, and Biotech Blog Posts<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Related Reports<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Non-Cystic Fibrosis Bronchiectasis Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Get comprehensive historical and forecast analysis of <\/span><span>Non-Cystic Fibrosis Bronchiectasis<\/span><span> Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as&nbsp;<\/span><span><strong>Aradigm Corporation, Zambon, Novartis Pharmaceuticals, Insmed Incorporated,<\/strong>&nbsp;<\/span><span>among others.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/span><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Sandeep Joshi<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=the-bronchiectasis-market-outlook-is-expected-to-change-positively-in-the-upcoming-years-because-of-increased-global-healthcare-spending-improved-awareness-and-the-proliferation-of-major-players\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=the-bronchiectasis-market-outlook-is-expected-to-change-positively-in-the-upcoming-years-because-of-increased-global-healthcare-spending-improved-awareness-and-the-proliferation-of-major-players\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bronchiectasis Market The launch of therapies such as Brensocatib\/INS 1007 and others are anticipated to provide a major push to the growth of the Bronchiectasis market size in the forecast period 2021-30 in the 7MM. DelveInsight&#8217;s Bronchiectasis market report provides &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/the-bronchiectasis-market-outlook-is-expected-to-change-positively-in-the-upcoming-years-because-of-increased-global-healthcare-spending-improved-awareness-and-the-proliferation-of-major-players_556732.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,420,403,404],"tags":[],"class_list":["post-556732","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/556732","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=556732"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/556732\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=556732"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=556732"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=556732"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}